Myovant Sciences Pre-Tax Profit Margin 2017-2022 | MYOV
Myovant Sciences pre-tax profit margin from 2017 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Myovant Sciences Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2022-03-31 |
$0.23B |
$-0.20B |
-87.01% |
| 2021-12-31 |
$0.20B |
$-0.23B |
-114.14% |
| 2021-09-30 |
$0.15B |
$-0.24B |
-164.14% |
| 2021-03-31 |
$0.06B |
$-0.25B |
-430.51% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.033B |
$0.231B |
|
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
|
